Abstract. Patients with ulcerative colitis (UC) and Crohn's disease have an increased risk for developing cancer of the colon. Mutations in the K-ras gene are relatively frequent in specimens from patients with sporadic colon cancer, but less frequent in cases of cancer complicating ulcerative colitis. In order to study the problem further we used the polymerase chain reaction (PCR) technique followed by a restriction fragment length polymorphism (RFLP) assay, to detect mutations at codon 12 of K-ras in biopsy specimens from patients with UC or Crohn's disease. Six among 27 patients (22.2%) with UC and 2 of the 19 patients (10.5%) with Crohn's disease examined, carried a mutation at codon 12 of K-ras. Our results indicate that mutations in K-ras may be a genetic marker that would reveal the predisposition to colon cancer among this group of patients.
Introduction
Ulcerative colitis (UC) and Crohn's disease are inflammatory disorders which predispose patients for the development.of colon cancer (1) . The risk for the development of cancer is 20-30 fold elevated in patients with UC for 10-20 years, when compared to the general population. Crohn's disease exhibits a lower risk, estimated to be about one third of the rate found in UC (1, 2) .
Histologically, UC is associated with a dysplasia that may expand to affect large areas of the mucosa, in which multiple aneuploid cell clones coexist. A subpopulation of one of these clones has been proposed to give rise to an invasive carcinoma ( 1 ) .
Genetic alterations such as ras and p53 mutations, allelic loss at loci on chromosomes 5q, 17q and 18q at relatively high frequences, have been reported in colon cancer (3) . Some of these disorders are reported to be related etiologically to the promotion of the malignancy. It would be very helpful to determine whether some specific genetic K-ras, Η-ras and N-ras oncogenes are members of the ras family of genes. The three genes code for structurally and immunologically related proteins of 21 kD, known as ras p21. ras p21 is located on the inner side of the plasma membrane, possesses GTPse activity and is involved in a signal transduction pathway (4). Transforming mutations in ras genes are found in about 50% of the human epithelial neoplasms and they have a crucial role in the progression of the malignancy.
K-ras mutations are relatively frequent in colon cancer and in UC and Crohn's disease they have been reported to exist in various frequencies (5) (6) (7) . The aim of the present study was to determine whether K-ras mutations play a role in the pathogenesis of invasive carcinoma in UC and Crohn's disease. We detected K-ras mutations at codon 12 in 22.2% of patients with UC and 10.5% in patients with Crohn's disease.
Materials and methods
Clinical specimens. Paraffin-embedded tissue sections from 27 biopsies from ulcerative colitis and 19 from Crohn's disease, were obtained from the Department of Gastroenterology of the University Hospital, Heraklion, Greece. Lesions with dysplasia or cellular atypia are shown in Table I (ulcerative colitis) and Table II (Crohn's disease).
DNA extraction. Three 10 μ thick sections from paraffinembedded tissue were put in 1.5 ml Eppendorf tubes and 400 μΐ digestion buffer containing 100 mM NaCl, 10 mM Tris, 25 mM EDTA and 0.5% SDS was added. Samples were incubated with 100 mg/ml proteinase Κ in 60°C for 1 h and then extracted twice with equal volume of phenolxhloroform (1:1) and once with chloroform. Supernatants were transferred into fresh tubes and DNA was precipitated with 2.5 volumes of 100% ethanol and 1/20 volume of 5 M NaCl. DNA was recovered with centrifugation for 15 min at 4°C, washed twice with ice cold 70% ethanol dried and resuspended in 20 μΐ distilled water.
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Oligonucleotide primers and PCR amplification. The oligonucleotide primers used for K-ras codon 12 and codon RFLP analysis. 10-20 μΐ aliquots of the amplification products were digested for 3 h with 20 U BstNl in 60°C for codon 12 and another 10-20 μΐ were digested overnight with Hph\ in 37°C for codon 13. The enzymes were purchased from New England Biolabs. Digestion products were electrophoresed through a 2% agarose gel, stained with ethidium bromide and photographed on a UV light transilluminator.
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Results
We analyzed 27 specimens from patients with chronic ulcerative colitis (UC) and 19 specimens from patients with Crohn's disease for the presence of K-ras mutations employing a PCR-RFLP analysis. Genomic DNA from the colon carcinoma cell line SW480, which is homozygous for a codon 12 K-ras mutation, was used as a positive control. Our results are summarised in Table I (ulcerative colitis) and  Table II (Crohn's disease). We found 5 heterozygous (patient numbers 4, 7, 24, 26 and 27) (18.5%) and 1 homozygous (patient number 25) or hemizygous (3.7%) mutation in codon 12 of K-ras among the 27 specimens from UC and 2 heterozygous (patients 14 and 17) (10.5%) mutations among the 19 specimens from Crohn's disease.
No correlation was found between K-ras mutations and high-grade dysplasia or cellular atypia in either ulcerative colitis or Crohn's disease samples, however the number of the specimens is low.
Representative results of the PCR-RFLP analysis are shown in Fig. 1 (ulcerative colitis) and Fig. 2 (Crohn's  disease) .
It is unlikely that the finding of K-ras mutations in our study represent PCR artifacts because DNA was extracted from various samples independently and the RFLP analysis which was positive for the mutations was performed twice for each sample. The results were identical on each occasion.
We also examined 15 specimens from UC for mutations in codon 13 of K-ras (8) . All the samples tested were negative for mutations (see Table I ).
Discussion
The fact that K-ra.v mutations in colon cancer are a relatively frequent genetic event, suggests that these mutations may play an important role in the tumorigenic progression of dysplasia from UC. The total number of K-ra.v mutations in specimens from UC in our study was 6 among 27 specimens (22.2%).
The results obtained from specimen number 25 in which only the mutant band for the codon 12 of K-ra.v appeared (Fig. 1, lane 2) . agrees with previous results that allelic losses is a fairly common genetical event in the progression of colon malignancy (9). Thus, it seems possible that this sample is not homozygous for the mutation but an allelic loss occured in its heterozygous previous state which left the mutant K-ra.v allele alone, in the cellular DNA. The lack of mutations in codon 13 of K-ra.v in 15 specimens of UC examined (Table I) shows a preference for codon 12 mutations of the K-ra.v gene in UC.
Specimens from patients with Crohn's disease carried Kras codon 12 mutations at a lower frequence than UC (2 out of 19 specimens) (10.5%). This finding agrees with the observation that Crohn's disease exhibits a lower risk for the development of colon cancer compared to UC (2) .
We suggest that codon 12 K-ra.v mutations may be implicated in the promotion of colon cancer from UC and Crohn's disease. Screening patients for K-ra.v mutations combined with another genetic marker, such as the p53 oncosuppressor gene (10) (11) (12) . may cluster patients with UC and Crohn's disease into subpopulations of increased risk for the development of colon cancer.
Furthermore, our results suggest that tumor progression between sporadic colon carcinoma and carcinomas arising in chronic ulcerative colitis or Crohn's disease may follow a different genetic pathway. 
